The cell cycle regulator CDC25A is a target for JAK2V617F oncogene

Blood

Volumn 119, Issue 5, 2012, Pages 1190-1199

  Gautier, Emilie Fleur ^a   Picard, Muriel ^a   Laurent, Camille ^a   Marty, Caroline ^b   Villeval, Jean Luc ^b   Demur, Cécile ^a   Delhommeau, François ^b,c   Hexner, Elizabeth ^d   Giraudier, Stéphane ^a,e   Bonnevialle, Nicolas ^a   Ducommun, Bernard ^a,f   Récher, Christian ^a   Laurent, Guy ^a   Manenti, Stéphane ^a   Mansat De Mas, Véronique ^a  

^a CHU PURPAN   (France)

^b Universite Paris Sud   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e HENRI MONDOR HOSPITAL   (France)

^f UPS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; INITIATION FACTOR 2ALPHA; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE CDC25A; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ERYTHROBLAST; ERYTHROID CELL; GAIN OF FUNCTION MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MYELOFIBROSIS; NONHUMAN; ONCOGENE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROERYTHROBLAST; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN CELL; THROMBOCYTHEMIA; TRANSLATION REGULATION; UPREGULATION; WILD TYPE;

EID: 84856599979     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-327742     Document Type: Article

References (35)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
5. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
6. Marty C, Lacout C, Martin A, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knockin mice. Blood. 2010;116(5):783-787.
7. Walz C, Crowley BJ, Hudon HE, et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006;281(26):18177-18183. (Pubitemid 44035617)
8. Lelièvre H, Cervera N, Finetti P, et al. Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators. Leukemia. 2006;20(10):1885-1888. (Pubitemid 44575001)
9. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7(7):495-507. (Pubitemid 46985396)
10. Chen X, Prywes R. Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression. Mol Cell Biol. 1999;19(7):4695-4702. (Pubitemid 29289507)
11. Santoni-Rugiu E, Falck J, Mailand N, Bartek J, Lukas J. Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol. 2000;20(10):3497-3509. (Pubitemid 30243895)
12. Barr é B, Vigneron A, Coqueret O. The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter. J Biol Chem. 2005;280(16):15673-15681.
13. Busino L, Chiesa M, Draetta GF, Donzelli M. Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene. 2004;23(11):2050-2056. (Pubitemid 38496734)
14. Khaled AR, Bulavin DV, Kittipatarin C, et al. Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biol. 2005;169(5):755-763. (Pubitemid 41002881)
15. Kang T, Wei Y, Honaker Y, et al. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell. 2008;13(1):36-47. (Pubitemid 350309739)
16. Pereg Y, Liu BY, O'Rourke KM, et al. Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. Nat Cell Biol. 2010;12(4):400-406.
17. Ray D, Terao Y, Fuhrken PG, et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 2007;67(3):984-991.
18. Ray D, Terao Y, Nimbalkar D, et al. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res. 2007;67(14):6605-6611. (Pubitemid 47105505)
19. Fernandez-Vidal A, Ysebaert L, Didier C, et al. Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia. Cancer Res. 2006;66(14):7128-7135. (Pubitemid 44197690)
20. Fernandez-Vidal A, Mazars A, Gautier EF, Prevost G, Payrastre B, Manenti S. Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. Cell Cycle. 2009;8(9):1373-1379.
21. Brezak MC, Valette A, Quaranta M, et al. IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int J Cancer. 2009;124(6):1449-1456.
22. Lavecchia A, Di Giovanni C, Novellino E. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. Expert Opin Ther Pat. 2010;20(3):405-425.
23. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006;107(10):4139-4141. (Pubitemid 43726824)
24. Chaligné R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22(8):1557-1566.
25. Löffler H, Syljuasen RG, Bartkova J, Worm J, Lukas J, Bartek J. Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines. Oncogene. 2003;22(50):8063-8071. (Pubitemid 37487297)
26. Gebauer F, Hentze MW. Molecular mechanisms of translational control. Nat Rev Mol Cell Biol. 2004;5(10):827-835. (Pubitemid 39336276)
27. Tomko RJ Jr, Lazo JS. Multimodal control of Cdc25A by nitrosative stress. Cancer Res. 2008;68(18):7457-7465.
28. Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans. 2006;34(Pt 1):7-11. (Pubitemid 43235522)
29. Bevilacqua E, Wang X, Majumder M, et al. eIF2alpha phosphorylation tips the balance to apoptosis during osmotic stress. J Biol Chem. 2010;285(22):17098-17111.
30. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338(9):564-571. (Pubitemid 28114644)
31. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene. 1998;16(11):1383-1390. (Pubitemid 28151845)
32. Garçon L, Rivat C, James C, et al. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood. 2006;108(5):1551-1554. (Pubitemid 44316120)
33. Furuhata A, Kimura A, Shide K, et al. p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation. Biochem Biophys Res Commun. 2009;383(4):411-416.
34. Dupont S, Masse A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110(3):1013-1021. (Pubitemid 47267441)
35. Kiss R, Sayeski PP, Keseru GM. Recent developments on JAK2 inhibitors: a patent review. Expert Opin Ther Pat. 2010;20(4):471-495.